Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) As Second-Line (2L) Therapy in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): First Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry
María Silvina Odstrcil Bobillo(University of Utah), Matthew J. Frigault(Harvard University), Catherine J. Lee(University of Utah), Tracy Krimmel(Bristol-Myers Squibb (United States)), Dasom Lee(Stanford Medicine), Saurabh Dahiya(Stanford University), Alex F. Herrera(City of Hope), Krish Patel, Sairah Ahmed(The University of Texas MD Anderson Cancer Center), David Bernasconi(Bristol-Myers Squibb (United States)), Bradley D. Hunter(Intermountain Healthcare), Ogechukwu Egini(Rutgers, The State University of New Jersey), Patrick M. Reagan(University of Rochester), Marcelo C. Pasquini(Cleveland Clinic), Jennifer L. Crombie(Dana-Farber Cancer Institute), Soyoung Kim(Medical College of Wisconsin), Swetha Kambhampati(City Of Hope National Medical Center), Charimar Santiago Parrilla(Medical College of Wisconsin), Debasmita Roy(Bristol-Myers Squibb (United States)), Fei‐Fei Liu(Jiangsu Hengrui Medicine (China)), Mazyar Shadman(University of Washington), Mehdi Hamadani(Medical College of Wisconsin)
Cited by 7
Related Papers
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
|JAMA|2021|723
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
|Journal of Clinical Oncology|2017|664
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|560